中藥配伍的禁忌：十八反與十九畏應用探討

Traditional Chinese Medicine Compatibility Taboo : Application Discussion of the Eighteen Toxic Interactions and the Nineteen Counteracting Interactions

吳柏鋒(Bo-Feng Wu)

《中醫藥研究論叢》 20卷2期 (2017/09) Pp. 51-59

https://doi.org/10.6516/TJTCM.2017.20(2)51

摘要

關於中藥配伍的禁忌，本文從《神農本草經》的七情配伍為起點，根據歷史文獻的記載與演進，了解十八反與十九畏論述形成的背景與意義。而且本文整理了現代實驗研究成果，從化學成分、藥理與毒理的角度探討這些配伍禁忌的合理性。除此之外，更結合古代文獻記錄與各醫家的用藥經驗加入討論，幫助我們更好理解十八反與十九畏並非絕對禁忌，只是臨床治療還需根據病情病機條件謹慎運用。

關鍵字

十八反 ； 十九畏 ； 配伍禁忌 ； 相惡

並列摘要

About Traditional Chinese Medicine compatibility taboo, this article stated from the seven prescription compatibilitys of ＂Shennong's compendium of materia medica＂, and with the records and development of the historical literatures, we could understand the background and significance of the eighteen toxic interactions and the nineteen counteracting interactions theory formation. With the collections of modern experimental research results, this article discussed the rationality of these compatibility taboo according to the conception of chemical compositions, pharmacology and toxicology. In addition, this discussion combined with the ancient literature records and the prescription experience of physicians could help us realize that the eighteen toxic interactions and the nineteen counteracting interactions theory is not an absolutely taboo. But in clinic al treatment, the prescription compatibility application of physicians must accord to the condition of pathogenesis and be cautious.

並列關鍵字

The eighteen toxic interactions ； The nineteen counteracting interactions ； Compatibility taboo ； The eliminating interactions

參考文獻

顏正華編(2011)。中藥學。台北:知音出版社。

朱良春、何紹奇(1998)。為“十八反”平反。中國中醫基礎醫學雜誌。4(4)，16-17。

龐晶瑤、趙奎君、李奇、馬致潔、賈歌劉暢(2014)。中藥十八反的相關研究近況。國際中醫中藥雜誌。36(9)，862-864。

范欣生、尚爾鑫、陶靜、華浩明、楊環、段金廒(2011)。“十八反”同方配伍探討。中醫雜誌。52(12)，991-994。

陶麗華、程顏彬、洪觀銀(2004)。中藥的“十九畏與十八反”與中藥的配伍禁忌。人參研究。4，18-22。